FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.

Genomics in Drug Discovery and Development

D Semizarov
    Product form
      FORMAT: Hardback

      R 5,860.00 Price and availability exclusive to website

      YOU COULD EARN 5,860 FUTURE RETAIL DISCOUNTS.
      ESTIMATED DELIVERY: Approx. 20 - 30 Business Days
      BUY NOW PAY LATER
      From R 976.66 per month!
      3x monthly payments of R 1,953.33 with
      4x fortnightly payments of R 1,465.00 with
      Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
      Format: CONTRIBUTORS: D Semizarov EAN: 9780470096048 COUNTRY: United States PAGES: WEIGHT: 839 g HEIGHT: 236 cm
      PUBLISHED BY: John Wiley & Sons Inc DATE PUBLISHED: 2008-11-14 CITY: GENRE: MEDICAL / Pharmacology WIDTH: 160 cm SPINE:

      Book Themes:

      Genetic engineering, Industrial chemistry and chemical engineering

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Dimitri Semizarov, PhD, is a Senior Group Leader in the Cancer Research Department of Abbott Laboratories' Global Pharmaceutical R&D. Dr. Semizarov leads cancer genomics research at Abbott, applying genomics technologies to enable personalization of cancer therapy. He is author or coauthor of more than twenty scientific articles and eight patent applications, as well as three book chapters (including two chapters in Wiley's Preclinical Development Handbook). Eric Blomme, DVM, PhD, Diplomate, American College of Veterinary Pathologists, is a Senior Project Leader for Cellular, Molecular, and Exploratory Toxicology in Global Pharmaceutical R&D at Abbott Laboratories. He has extensive drug discovery, toxicology, and screening experience working for Abbott, Pharmacia, Monsanto, Searle, Ohio State University, and Cornell University. Dr. Blomme has written over fifty journal articles and eight book chapters, and is a reviewer for multiple scientific journals in the fields of toxicology and pathology.
      Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
      Format: CONTRIBUTORS: D Semizarov EAN: 9780470096048 COUNTRY: United States PAGES: WEIGHT: 839 g HEIGHT: 236 cm
      PUBLISHED BY: John Wiley & Sons Inc DATE PUBLISHED: 2008-11-14 CITY: GENRE: MEDICAL / Pharmacology WIDTH: 160 cm SPINE:

      Book Themes:

      Genetic engineering, Industrial chemistry and chemical engineering

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Dimitri Semizarov, PhD, is a Senior Group Leader in the Cancer Research Department of Abbott Laboratories' Global Pharmaceutical R&D. Dr. Semizarov leads cancer genomics research at Abbott, applying genomics technologies to enable personalization of cancer therapy. He is author or coauthor of more than twenty scientific articles and eight patent applications, as well as three book chapters (including two chapters in Wiley's Preclinical Development Handbook). Eric Blomme, DVM, PhD, Diplomate, American College of Veterinary Pathologists, is a Senior Project Leader for Cellular, Molecular, and Exploratory Toxicology in Global Pharmaceutical R&D at Abbott Laboratories. He has extensive drug discovery, toxicology, and screening experience working for Abbott, Pharmacia, Monsanto, Searle, Ohio State University, and Cornell University. Dr. Blomme has written over fifty journal articles and eight book chapters, and is a reviewer for multiple scientific journals in the fields of toxicology and pathology.

      Recently viewed products

      Login

      Forgot your password?

      Don't have an account yet?
      Create account